Abstract: Cyclosporine has been con train di ca ted in patients with chro nic infec tions such as infec tion with hepa ti tis C becau se of its immu no sup pres si ve effect. Recent stu dies have shown howe ver that cyclos po rine sup pres ses viral repli ca tion and thus can not exa cer ba te infec tion with hepa ti tis C when emplo yed for trea ting patients with pso ria sis. We pre sent the case of a fema le patient with pso ria sis for 30 years and hepa ti tis C for 20 years, with dif fu se cir ci na te lesions. Improvement in the skin con di tion and liver enzymes was obtai ned with the use of cyclos po ri ne, with no adver se effect. Keywords: Cyclosporine; Hepatitis C; Psoriasis Resumo: A ciclos po ri na tem sido con train di ca da nos pacien tes com infec ções crô ni cas, como a infec ção pelo vírus da hepa ti te C, devi do ao seu efei to imu nos su pres sor. No entan to, estu dos recen tes têm demonstra do que a ciclos po ri na supri me a repli ca ção viral e pode, desta forma, não exa cer bar a infec ção pelo vírus da hepa ti te C, quan do admi nis tra da como tra ta men to para pacien tes com pso ría se. Apresentamos o caso de uma pacien te por ta do ra de pso ría se há 30 anos e hepa ti te C há 20 anos, com lesões cir ci na das difu sas, que apre sen tou melho ra cutâ nea e das enzi mas hepá ti cas com o uso da ciclos po ri na, sem apre sen tar nenhum efei to adver so.
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INTRODUCTION
With the increased incidence and/or prevalence of infectious diseases, including infection with hepatitis C (3% of world population), it is not uncommon in clinical practice for patients to present with both psoriasis and hepatitis C, which makes treatment a challenge for the dermatologist. 1 Systemic treatment of psoriasis is performed with so-called conventional drugs such as methotrexate, cyclosporin and acitretin, as well as with immunobiological medicines. 2 The choice of medication depends on patient variables such as age, sex, co-morbidities, underlying diseases, lifestyle etc. Hepatitis C is mainly treated with a combination of interferon (which works directly against the virus and boosts immune response) with ribavirin (synthetic analogue of guanosine which acts directly on RNA and DNA viruses). 3.4 In patients with psoriasis and hepatitis C, interferon exacerbates psoriasis and the hepatotoxicity and immunosuppression caused by the majority of therapies for psoriasis treatment, which could worsen the hepatitis C infection. It is therefore contraindicated in these conditions. However, recent findings on the anti-viral effect of ciclosporin on the hepatitis C virus have opened new prospects for using it safely and effectively in patients with psoriasis and hepatitis C. 
CASE REPORT
Female patient, 75 years old, diagnosed with plaque psoriasis treated with topical drugs for over 30 years, with worsening of skin lesions over previous 6 months. The lesions became more erythematous, pustular, pruritic and painful, with scaly edges. The patient (current weight 51kg) admitted to no other systemic symptoms. Dermatological examination revealed erythematous, circinate scaly edges on upper and lower limbs, the inframammary region, trunk and face (Figures 1 and 2) . Past medical history of hepatitis C when clinically monitored in hepatology service 20 years previously, with worsening of liver function in the last year.
Skin biopsy and laboratory tests showed altered liver enzymes (Table 1) . Cyclosporine 3mg/kg/day was started and after 8 weeks the patient showed improvement of skin lesions ( Figure 3 ) and liver enzymes. The PASI score decreased from 27 to 9, with a serum cyclosporine value of 219 ng / ml.
DISCUSSION
Circinate pustular psoriasis or pustular ring is a localized form of pustular psoriasis manifested by outbreaks of annular lesions, with erythema and pustules on the periphery, generally located on the trunk and roots of members with no systemic manifestation. It is rare condition and typical psoriasis lesions are usually not present.
Cyclosporine is an immunosuppressive medication that can be very useful for the treatment of psoriasis. It belongs to the family of calcineurin inhibitors and acts as a prodrug since it remains inactive until it connects with its cytoplasmic receptor known as cyclophilin. 2 The cyclosporin-cyclophilin complex inhibits calcineurin phosphatase activity, leading to inhibition of T-cell function and to decreased production of IL-2 (interleukin 2). The recommended daily dose for the treatment of psoriasis is 3-5mg/kg/day.
2.3
Using cyclosporine is at present contraindicated for patients with difficult-to-control arterial hypertension, renal dysfunction and T-cell lymphoma. 3 It also involves a number of relative contraindications such as breastfeeding, the use of other immunosuppressants, migraine and in patients with chronic infections. Therefore a good clinical and laboratory evaluation of the patient is needed before using this medication. Due to the risk of nephrotoxicity, hypertension and malignancy, the use of cyclosporine should be used for a minimum length of time. 1, 2, 3 A patient´s inability to generate an effective immune response is one factor which causes an infection to become established and maintain its chronicity, as in the case of patients with hepatitis C. This explains why cyclosporine is traditionally contraindicated in patients with chronic infections 4 . Recent studies nevertheless demonstrate that cyclosporine acts as a mechanism for suppressing the viral replication of HCV. This occurs by inhibiting the functional association of intracellular cyclophilin (a cofactor for viral replication) with the viral protein NS5B (crucial viral protein for viral replication), thus decreasing the HCV viral load and leading to improved liver function in some cases. 4.5 Studies also suggest that the HCV genotype 1b is the most sensitive to inhibition by cyclosporine given that it is dependent on the cyclophyn for replication. 6.7 Evidence also exists that the inhibitory effect of cyclosporine on HCV viral replication (by blocking cyclophyn) is independent of the immunosuppressive function of cyclosporine, which is achieved through the inhibition of calcineurin. 7.8 The use of cyclosporine in patients with psoriasis and hepatitis C improves skin condition without exacerbating hepatitis. In some cases it may even lead to improvement in liver function and viremia. 8.9 The case described above showed clinical improvement with the use of cyclosporine, as well as improvement of liver enzymes, with no adverse effects.
These recent findings of the anti-HCV effect of cyclosporine renew the prospects for considering this drug to be a good option for treating psoriasis in patients with hepatitis C. Although more studies on its safety and efficacy are called for (the literature contains only a few case reports) it can be used with caution. q 
